Matrix Metalloproteinase-9 and Haemozoin:  Wedding  Rings for Human Host and  Plasmodium  falciparum Parasite in Complicated Malaria by Prato, Mauro & Giribaldi, Giuliana
Hindawi Publishing Corporation
Journal of Tropical Medicine
Volume 2011, Article ID 628435, 11 pages
doi:10.1155/2011/628435
Review Article
Matrix Metalloproteinase-9 and Haemozoin:Wedding
Rings forHuman Hostand Plasmodiumfalciparum Parasitein
Complicated Malaria
Mauro Pratoand GiulianaGiribaldi
Dipartimento di Genetica, Biologia e Biochimica, Facolt` a di Medicina e Chirurgia, Universit` a di Torino, Via Santena 5 bis,
10126 Torino, Italy
Correspondence should be addressed to Mauro Prato, mauro.prato@unito.it
Received 31 December 2010; Accepted 7 March 2011
Academic Editor: Sasithon Pukrittayakamee
Copyright © 2011 M. Prato and G. Giribaldi. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
It is generally accepted that the combination of both Plasmodium falciparum parasite and human host factors is involved
in the pathogenesis of complicated severe malaria, including cerebral malaria (CM). Among parasite products, the malarial
pigment haemozoin (HZ) has been shown to impair the functions of mononuclear and endothelial cells. Diﬀerent CM models
were associated with enhanced levels of matrix metalloproteinases (MMPs), a family of proteolytic enzymes able to disrupt
subendothelial basement membrane and tight junctions and shed, activate, or inactivate cytokines, chemokines, and other MMPs
throughcleavagefromtheir precursors. AmongMMPs,agoodcandidatefortargeted therapy mightbeMMP-9,whosemRNA and
protein expression enhancement as well as direct proenzyme activation by HZ have been recently investigated in a series of studies
by our group and others. In the present paper the role of HZ and MMP-9in complicated malaria,as well as their interactions, will
be discussed.
1.Introduction
Among protozoan parasites of the genus Plasmodium, P. fal-
ciparum is the most deadly agent of human malaria, causing
a broad spectrum of clinical manifestations ranging from
asymptomatic to severe multiorgan disease. Despite recent
major eﬀorts by the research community, malaria remains
one of the major diseases in poor areas, including Sub-
Saharan Africa and South-East Asia. It is associated with
several million clinical cases per year and leads annually to
overone million deaths[1, 2].The pathophysiologyofsevere
malaria complications is not well understood. In some cases,
including cerebral malaria (CM), renal failure, lung patholo-
gy and malaria during pregnancy, it appears associated with
cytoadherenceand sequestration of P. falciparum-parasitized
red blood cells (pRBCs) to vascular endothelium, leading to
microcirculatory obstruction, tissue hypoxia, and metabolic
disturbances [3–5]. In some cases additional leukocyte
extravasation has been reported [6, 7].
As described in the following sections, either pRBCs
or parasite products such as haemozoin (HZ, malarial
pigment), a lipid-enriched ferriprotoporphyrin IX crystal
derived from haemoglobin catabolism by the parasite [8],
can modulate the functions of mononuclear and endothelial
cells and promote the production of proinﬂammatory
molecules and other soluble factors, including matrix metal-
loproteinases (MMPs). MMPs are a well-known family of
proteolyticenzymes able to disrupt subendothelial basement
membranes [9, 10], to destroy tight junctions [11], and to
shed,activate, orinactivatecytokines,chemokines, andother
MMPs through cleavage from their precursors [12–14]. In
the last decade, growing evidence on involvement of MMPs
in falciparum malaria became available: human postmortem
studies showed enhanced protein levels of MMP-1 in brains
of CM patients [15], whereas MMP-8 was found increased
in plasma of severe malaria patients [16]; additionally,
activation of the human MMP-9 gene by P. falciparum has
been reported in microarray studies on whole blood from2 Journal of Tropical Medicine
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Figure 1: Eﬀects of phagocytosis of HZ on human monocyte functions.
children with malaria [17]. Interestingly, a role for MMPs
duringmalaria issuggestedalsobyevidencefrom nonhuman
models of CM: in the brain of mice infected by P. Berghei
ANKA,the etiological agent of murine CM, increased MMP-
2, MMP-7, and MMP-9 levels, and pro-MMP-9 activation
were found [18, 19].
The present paper will explore the eﬀects of HZ on
functions of mononuclear and endothelial cells, focusing on
regulation of human MMP-9, which at present among the
malaria-related MMPs is the most studied and could be a
potential target for adjunctive therapy of complicated severe
malaria.
2.EffectsofHZ onHumanMononuclearand
EndothelialCells
HZ is a birefringent crystalline material made of Fe3+-
Protoporphyrin IX dimers that derives from the degra-
dation of haemoglobin by intraerythrocytic Plasmodium
[8]. Unpuriﬁed HZ contains also unspeciﬁcally attached
polyunsaturated fatty acids (PUFAs)such as arachidonic and
linolenic acids, originating from membranes of Plasmodium
digestive vacuoles [20]. The presence in unpuriﬁed HZ of
large quantities of ferric haem with small amounts of free
iron makes HZ a generator of oxidative radicals capable of
forming lipoperoxides or other breakdown products from
PUFAs(quasilipoxygenaseactivity) [21].Analysisofthelipid
fraction isolated from native HZ showed large amounts
ofhydroxyeicosatetraenoic acids(HETEs), hydroxyoctadeca-
dienoicacids(HODEs),andtheterminalaldehyde4-hydrox-
ynonenal (4-HNE) [22].
HZ is avidly phagocytosed by human monocytes, and
the fatal risk for patients with severe falciparum malaria has
been reported to be directly proportional to levels of HZ-
containing monocytesin peripheralblood[25].Afterphago-
cytosis of HZ, several monocyte functions are dramatically
impaired, as shown in Figure 1.T h ee ﬀects of HZ on human
monocytesareeitherinhibitingorstimulating.Adetrimental
case of functional inhibition led by HZ phagocytosis is
represented by immunodepression. As evidenced from in
vitrostudies, HZ-fed human monocytes showed impairment
of repeated phagocytosis [26], bacterial killing abilities [27],
and oxidative burst [28]. Additionally HZ-laden monocytes
did not respond to IFN-gamma stimulation and failed
in MHC Class II expression, with following disturbances
in antigen presentation [29]. These eﬀects appear to be
dependent on the lipid moiety of HZ, and low doses of 4-
HNE have been reported to mimic HZ action by inhibiting
the IFN-gamma-mediated MHC Class II expression [30].
On the contrary, the inhibitory role of HZ on monocyte
diﬀerentiation/maturationtodendriticcellsislessclear,since
similar in vitro studies by diﬀerent authors led to opposite
results, showing either inhibition [31] or enhancement
[32, 33]o fd i ﬀerentiation/maturation to dendritic cells. HZ
appears also to be related indirectly to anaemia, as HZ-
fed monocytes are not able to coordinate the maturation
of erythroid precursors; also in this case a role for 4-
HNE in HZ-dependentinhibition of erythropoiesis has been
proposed [34]. Regarding the stimulating eﬀects of malarialJournal of Tropical Medicine 3
pigment, HZ-laden monocytes have been shown to overpro-
duce a large series of proinﬂammatory molecules, including
cytokines (TNF, IL-1 beta, and IL-1RA), chemokines (IL-
8/CXCL8, ENA-78/CXCL5, GROα,G R O β,G R O γ,M I P -
1α,M I P - 1 β, and MCP-1) and the cyto/chemokine-related
proteolytic enzyme MMP-9 [23, 35–38]. The lipid moiety of
HZ appears to be responsible for these eﬀects, and a major
role for 15-HETE has been proposed. Due to the important
direct connections to MMP-9, the mechanisms underly-
ing the HZ-triggered pro-inﬂammatory response will be
deeply discussed in a following dedicated section. Curiously,
although HZ compromises a large number of monocyte
functions, leading to rapid inﬂammatory response, it has
been recently shown that HZ-laden monocytes do not
undergo apoptosis. To explain such an apparent dichotomy,
a role for heat shock protein-27 (HSP-27), a chemokine-
dependent molecule with antiapoptotic properties, has been
recently proposed by our group. Indeed, in two models
in vitro we showed HZ-dependent upregulation of HSP-27
either in immunopuriﬁed monocytes from peripheral blood
or in the THP-1 monocytic cell line [38, 39].
Anyway, phagocytic cells such as monocytes are not the
only human cells which appear to be inﬂuenced by HZ. Few
data are also available on direct alterations of the human
endothelial cell phenotype by HZ. Such a change might
be dramatically detrimental during CM, since endothelial
cells are a crucial component of the blood-brain barrier
(BBB). At present, HZ has been reported to enhance either
basal or cytokine-induced levels of adhesion molecules
[40, 41] and to inhibit the release of the vasoconstrictor
mediator ET-1 [42–44]. Additionally, recent evidence from
human microvascular endothelial cells (HMECs) as well as
human umbilical vein endothelial cells (HUVECs) showed
enhancement or de novo induction of protein expression
and activity of several MMPs, including MMP-1, MMP-3,
and MMP-9. This topic will be deepened in the following
sections.
3.Involvement ofMMP-9 in Complicated
SevereMalaria
MMP-9 is produced by several cells, including mononuclear
and endothelial cells.
Structurally, MMP-9 shares with the other members of
the MMP family the following conserved domains: a prodo-
main, an active domain, a Zn2+-binding domain and a car-
boxyterminalhaemopexindomain(whichisabsentinMMP-
7 and MMP-26). In addition MMP-9, as well as the other
gelatinaseMMP-2,has agelatin-bindingﬁbronectindomain,
composed of three ﬁbronectin repeats, inserted between the
active-site domain and the Zn2+-binding domain, plus an
additional collagen type V domain in a particular hinge
region. The Zn2+-binding domain, which contains three his-
tidines responsible for the coordination of the catalytic Zn2+
ion, forms the active site with the active domain and is
required for the enzymatic activity. The fourth ligand of the
Zn2+ ion is a cysteine of the prodomain. This propeptide can
be removed by proteolysis or distorted by substrate binding.
The haemopexin domain plays a role in the substrate
speciﬁcity and is important for the binding of the tissue
inhibitors of metalloproteinases (TIMPs). The ﬁbronectin
repeats are related to gelatin, laminin, and collagens I/IV
binding [9, 10, 45].
In the last decade, few evidence of direct involvement of
MMP-9 in severe malaria has been reported. Activation of
the human MMP-9 gene by P. falciparum has been shown in
microarray studiesonwhole blood fromchildrenwith severe
malaria [17], whereas MMP-9 increases in cerebrospinal
ﬂuid levels were not apparent, possibly because of the
enzyme’s tight association with the extracellular matrix [46].
At present no studies of MMP-9 in human postmortem brain
tissues have been reported, but MMP-9 levels have been
shown to be strongly upregulated in C57BL/6 mice brain
infected with P. berghei ANKA, a murine model of CM
sharing similar characteristics with human CM. Elevated
MMP-9 levels were selective for the central nervous system,
where they were found associated with the vasculature
and parenchyma whereas immunohistochemistry showed
that higher amounts of MMP-9 were produced by cells of
monocytic lineage (CD11b+) [18].
Activation of pro-MMP-9 by removal of the propeptide
may occur through several proteolytic mechanisms. It is
well known that it can be processed and further activated
through a proteolyticcascade involving plasminogen, MMP-
3 and MMP-1 [13, 47–49]. Interestingly, an accumulation of
urokinase-type plasminogen activator receptor (uPAR) and
MMP-1 has been described in brain of patients who died
with CM [15, 50]. Furthermore, increased levels of MMP-
3 in brain and spleen were observed in the murine model of
CM previously cited [18]. Alternative mechanisms for pro-
MMP-9 activation involve MMP-2 [51] and MMP-7 [52].
Thesemoleculeshavenotbeenstudiedyetinhumanmalaria.
However,inCMmurinemodels, MMP-2mRNAandprotein
were upregulated in brain [18] and MMP-7 mRNA was
increased in liver but not in brain [18], whereas MMP-7
protein was increased in brain [19].
Aftersecretionandactivation,MMP-9activitycanstillbe
regulated by degradation or inhibition. MMP-9 is inhibited
not speciﬁcally by alpha2-macroglobulin and speciﬁcally by
TIMPs, TIMP-1 showing the highest aﬃnity for MMP-9
[53]. Inhibition of the activated MMP-9 occurs through
interaction between the N-terminal domains of TIMP-1 and
t h ea c t i v es i t eo ft h ee n z y m e[ 54]. The C-terminal part
of MMP-9 is also involved, and seems to be responsible
for high-aﬃnity interaction with TIMP-1 [55]. Recently,
Dietmann et al. measured serum levels of several TIMPs and
MMPs in patients with severe malaria [16]a n df o u n dt h a t
elevated TIMP-1 was associated with signs and symptoms
of severe malaria; in the same study the authors detected
increasedlevelsofMMP-8,butnotofMMP-9. MMP-9isalso
inhibited by a large number of synthetic compounds [56–
58]. Interestingly, antimalarial artemisinin- and artemisinin-
derived drugs also showed anti-MMP-9 properties [59–62].
Functionally, MMP-9 is able to process a large pattern of
molecules, including matrix proteins, inﬂammatory factors,
surface molecules, and intercellular junctions [12, 14].
Among these substrates, several have been associated to4 Journal of Tropical Medicine
Table 1: Substrates of MMP-9 that might be critical to complicated severe malaria.
MMP-9 substrate Functional classiﬁcation Eﬀect of MMP-9 proteolytic activity References
Pro-TNF Cytokine proform Shedding [63]
Pro IL-1beta Cytokine proform Activation [64]
IL-1beta Cytokine Degradation [65]
Pro-TGF-beta Cytokine proform Activation [66]
GRO-alpha/CXCL1 Chemokine Degradation [67]
PF-4/CXCL4 Chemokine Degradation [67]
ENA-78/CXCL5 Chemokine Transient potentiation, further inhibition [68]
GCP-2/CXCL6 Chemokine No eﬀects [68]
NAP-2/CXCL7 Chemokine Degradation [67]
IL-8/CXCL8 Chemokine Potentiation [67]
MIG/CXCL9 Chemokine Inhibition [69]
IP-10/CXCL10 Chemokine Degradation [69]
SDF-1/CXCL12 Chemokine Inhibition [70]
ICAM-1 Cell surface protein Inhibition [71]
IL-2R-alpha Cell surface protein Inhibition [72]
Occludin Intercellular junction Degradation [73]
ZO-1 Intercellular junction Degradation [74]
ZO-2 Intercellular junction Degradation (hypothesis) [75]
Claudin-1 Intercellular junction Degradation [76]
Claudin-2 Intercellular junction Degradation (hypothesis) [77]
Claudin-4 Intercellular junction Activation (hypothesis) [78]
Claudin-5 Intercellular junction Degradation (to be further investigated) [79]
Syndecan-1 Structural protein Shedding [80]
MBP Structural protein Degradation [81]
Beta-dystroglycan Structural protein Degradation [82]
severe malaria. Table 1 lists the principal MMP-9 substrates
which might be relevant for malaria studies. The indicated
molecules are either soluble factors (cytokines, chemokines)
or membrane-associated proteins (pro-TNF, cell surface
proteins, and intercellular junctions). All these molecules
appear to be crucial for the development of complications
of severe malaria, and their overbalanced regulation is often
associated to CM. This is characterized by cytoadherence
and sequestering of pRBCsto brain endothelial cells through
ICAM-1, followed by an elevated inﬂammatory response,
with high production of TNF and IL-1 beta, as well as
several chemokines, which might recruit mononuclear cells
and favour monocyte extravasation through the blood-brain
barrier (BBB), which appears leaky due to the disruption
of tight junctions ZO-1, claudin-5, and occludin [6, 7, 83–
90]. Thus, in order to better understand and eventually
prevent the mechanisms underlying CM, in the future it
will be certainly intriguing to investigate the eﬀects of
MMP-9 on these molecules in complicated severe malaria
models. Interestingly, the gene induction as well as the
direct activation of MMP-9 by HZ has been demonstrated
in vitro either in mononuclear or on endothelial cells, and
an active role for HZ-dependent enhancement of soluble
TNF production by human monocytes has already been
demonstrated [23], as it will be discussed in the following
section.
4.InteractionsbetweenHZ and MMP-9
The relationship between falciparum HZ and human MMP-
9, as well as several related molecules, has been investigated
in-depth in a series of recent works. In an elegant work
Geurts et al. demonstrated that pro-MMP-9 binds directly
to the beta-haematin core of HZ through its haemopexin
domain, resulting in priming of the activation of the zy-
mogen by other MMPs [91]. In human monocytes HZ has
been reported to inﬂuence the MMP-9 gene and protein ex-
pression, as well as following protein release. Experiments by
Real Time RT-PCR have shown that HZ and HZ-containing
trophozoites enhanced the mRNA expression of MMP-9
[23]. HZ-dependent MMP-9 gene induction was also con-
ﬁrmed by additional microarray [92]a n dm a c r o a r r a y[ 38]
studies. As a consequence, pro-MMP-9 protein expression
was found to be increased [23]. The degranulation of gel-
atinase granules with MMP-9, lysozyme, and TIMP-1 was
also promoted, as demonstrated by data showing HZ/tro-
phozoite-dependent enhanced release of active MMP-9 [23],
lysozyme [93, 94], and TIMP-1 [94] in monocyte cell super-
natants. As a result, the total gelatinolytic activity of mono-
cyteswas increased by HZ [94]a n dc e l l sw e r ea b l et om i g r a t e
through extracellular matrix [23].
The production of several soluble factors related to
MMP-9 has also been studied. HZ and trophozoites were
shown to stimulate the release of TNF [23]a n dI L - 1b e t aJournal of Tropical Medicine 5
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Figure 2: HZ-containing pRBCs (trophozoites) and free HZ enhance MMP-9 levels in HUVECs. Untreated cells (column/lane 1, both
panels), cells treated with uninfected RBCs or latex as control stimuli (column/lane 2, (a) and (b) resp.), and cells treated with HZ-
containing-trophozoites or HZ (column/lane 3, (a) and (b), resp.) were incubated for 48h. At the end of the treatment, MMP-9 levels were
measured in HUVEC supernatants by SDS-PAGE gelatin zymography and densitometric analysis through a computerized densitometer as
previously described [23, 24]. Column data (lower panels) are mean values of arbitrary densitometric units + SEM of three independent
experiments; gel data (upper panels) are from one representative experiment; the 83-kDa negative bands in the gel indicate MMP-9 levels.
Data were analyzed for signiﬁcance by Student’s t-test and all diﬀerences were signiﬁcant ((a) 1 versus 2: P<. 02; 1 versus 3: P<. 001; 2
versus 3: P<. 002. (b) 1 versus 2: P<. 001; 1 versus 3: P<. 0001; 2 versus 3: P<. 001).
[37] by human monocytes. These cytokines, which can
modulate the MMP-9 gene expression [95, 96], have been
shown to play a crucial role in HZ-dependent enhancement,
since the use of anti-TNF and anti-IL-1beta antibodies
abrogated thepreviousHZeﬀectsonpro-MMP-9 expression
and active MMP-9 release [23, 37]. Anti-TNF antibodies
also blocked the HZ-dependent r e l e a s eo fa c t i v el y s o z y m e
[93]. Interestingly, pro-TNF and pro-IL-1 beta are also
two molecular substrates of MMP-9 (see Table 1); as a
c o n s e q u e n c eo fc l e a v a g eb yM M P - 9 ,t h es o l u b l eT N Fi ss h e d
from itsmembrane-bound precursor[63], whereas IL-1 beta
is directly activated after removal of the propeptide [64].
The use of a synthetic inhibitor of MMP-9 was shown to
abrogate the HZ-dependent enhancement of TNF release by
human monocytes[23].Suchan evidencedemonstrated that
during malaria a pathological autoenhancing loop between
MMP-9 and TNF is likely, and the inhibition of MMP-9
couldbeparticularly importantinordertoavoiddetrimental
inﬂammatory eﬀectsduring complicated malaria, CM above
all. On the other hand, the MMP-9 inhibitor did not
alter the HZ-enhanced release of IL-1 beta [37], suggesting
that in HZ-fed monocytes the production of IL-1 beta
precedes the MMP-9 enhancement. This hypothesis was
conﬁrmed by recent time-dependent macroarray studies on
expression of inﬂammatory genes, showing that praecox
IL-1 beta mRNA expression was already present 2h after
exposure of human monocytes to HZ; therefore, IL-1beta
was rapidly endorsed by additional transcription of other
inﬂammatory genes, including MMP-9, TNF, IL-1RA, and
several chemokines (IL-8/CXCL8, ENA-78/CXCL5, GRO-
alpha/CXCL1, GRObeta, GRO-gamma, MIP-1 alpha, MIP-1
beta, and MCP-1) [38]. Moreover, crossed experiments with
anti-TNF and anti-IL-1beta blocking antibodies suggested
that the production of IL-1 beta was earlier than TNF
production [37].
Recently, the eﬀects of HZ on MMP-9 regulation have
beenalsostudiedinendothelialcells.MMP-9 proteinexpres-
sion and release was shown to be dose-dependently induced
de novo by HZ in HMECs and to enhance total gelatinolytic
activity; as a consequence, cells displayed morphological
changes, showing elongated shape and increased ability to
form microtubule-like structures through extracellular ma-
trix. In the same work, the enhanced expression of MMP-1
and MMP-3, two enzymes causally connected in the cascade
of activation of pro-MMP-9, was also described [97]. Addi-
tional data for endothelial cells from large calibre vessels are
described in Figure 2, showing that HZ and HZ-containing
trophozoites were able to enhance basal levels of activated
MMP-9 released in cell supernatants from HUVEC cultures.
Further studies performed either on mononuclear or
endothelial cells were aimed to clarify what component
(haem or lipid moiety) was responsible for the eﬀects of HZ
on MMP-9 and related soluble factors described above. In
human monocytes the use of delipidized native or lipid-free
synthetic HZ did not reproduce the enhancing eﬀects of HZ
on MMP-9 levels [37], gelatinolytic activity [94], lysozyme6 Journal of Tropical Medicine
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Figure 3: Putative mechanisms through which HZ and 15-HETE might promote NF-kappaB-controlled gene expression of MMP-9 and
related molecules.
release [94],and productionofTNF[98],IL-1 beta[37],and
several chemokines [38], suggesting a major role for the lipid
moiety of HZ. Further investigation suggested that a valid
candidateresponsiblefor HZstimulatoryeﬀectscouldbe15-
HETE, since micromolar doses of this compound mimicked
HZ eﬀects on all previous parameters [37, 38, 94, 98]. A role
for the lipid moiety of HZ has been also proposed to explain
the HZ eﬀects on HMECs, since delipidized and synthetic
HZ did not aﬀect MMP-9, MMP-3, and MMP-1 protein
expression [97].
Finally, a mechanism involving NF-kappaB activation
has been recently proposed to explain how HZ and 15-
HETE might promote the production of MMP-9 and related
molecules in human monocytes. After phagocytosis of HZ
and trophozoites, as well as stimulation with 15-HETE, the
phosphorylationanddegradationofcytosolicIkappaB-alpha
protein and the following nuclear translocation of the NF-
kappaB complex were promoted either in short-term (2h
after phagocytosis) or long-term (24h after phagocytosis)
studies. These events appeared directly related to HZ-
dependent enhancement of MMP-9 release and production
of TNF and IL-1 beta, since the use of NF-kappaB inhibitors
showing antimalarial properties (quercetin, artemisinin, and
parthenolide)abrogatedtheeﬀectsofbothHZand15-HETE
[61]. Additionally, the same inhibitors also abrogated the 15-
HETE enhancing eﬀects on total gelatinolytic and lysozyme
activity [94]. In another study using a monocytic cell line
(THP-1),anextractfromaplantwithantimalarial properties
(Punica granatum) inhibited HZ-dependent enhancement
of MMP-9 expression and secretion by blocking the NF-
kappaB-driven transcription [99]. The previous literature
data have shown that HETEs are peroxisome proliferator-
activated receptor-gamma ligands inhibiting the production
of inﬂammatory cytokines and suppressing the NF-kappaB
system. However, alternative mechanisms which might lead
to HETEs-driven NF-kappaB activation have also been doc-
umented. Aﬁrst alternative activation ofNF-kappaBis based
on HETE-mediated activation of protein kinase C [100–102]
which in turn activates IKK [103], the kinase responsible for
IkappaB-alpha phosphorylation and degradation [104], and
subsequent nuclear translocation of NF-kappaB. Transient
activation of protein kinase C by HZ [105]m a yt h u s
explain the ﬁrst NF-kappaB activation peak revealed 2h
after HZ phagocytosis. A second alternative activation ofJournal of Tropical Medicine 7
NF-kappaB [106] was found to involve MAP kinases, ERK,
and p38 cascade. The p38 cascade was also proposed for
HETEs-dependent modulation of TNF [107] and MMP-9
[108]. Interestingly, ERK-1/2 phosphorylation by HZ has
been documented in a murine system [109]. A third alter-
native activation of NF-kappaB may result from the direct
oxidation and inactivation of IkappaB by lipid hydroperox-
ides [110]. Figure 3 summarizes the putative mechanisms
throughwhichHZandHETEsmightactivatetheNF-kappaB
transcription system and promote the following enhance-
ment of gene induction of MMP-9 and related cytokines.
5.Conclusions
Evidence of the involvement of MMPs in complicated severe
malaria has been emerging during the last decade, and
HZ-dependent induction of MMP-9 expression and activity
has been demonstrated in mononuclear or endothelial
cells. Since several MMP inhibitors are already available
as potential therapeutic tools in other pathologies [55–57],
MMPs should be taken in account as potential new targets
for an innovative and adjunctive therapy for severe malaria.
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